Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TBC1D26 | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-06 |
mRNA | ZBED3 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
mRNA | POU2F1 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
mRNA | SUZ12 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
mRNA | CHAF1A | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
mRNA | APPL1 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
mRNA | SRSF12 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |
mRNA | ASPH | CTRPv2 | pan-cancer | AAC | -0.16 | 9e-06 |
mRNA | ATAD5 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |
mRNA | OSGIN1 | CTRPv2 | pan-cancer | AAC | -0.15 | 9e-06 |